Public Release: 

The advances in AI for pharma industry to be presented at AI & Blockchain Applications Workshop

InSilico Medicine, Inc.

IMAGE

IMAGE: Alex Zhavoronkov, CEO of Insilico Medicine, coordinates the AI & Blockchain Applications in Pharma R&D Executive Workshop in Basel, Switzerland. view more 

Credit: Insilico

Wednesday, May 23, 2018, Baltimore, MD - Insilico Medicine, a Baltimore-based company specializing in the application of artificial intelligence for drug discovery, biomarker development and aging research, announces the presentation of its CEO, Alex Zhavoronkov, at the AI & Blockchain Applications in Pharma R&D Executive Workshop, May 30-31, 2018, organized by NextLevel Pharma.

Dr. Zhavoronkov's workshop "Artificial Intelligence for Drug Discovery" will be devoted to the impact of the recent advances in AI on the pharmaceutical industry at every level of drug discovery process - from lead generation to clinical trials management and marketing. The presentation will provide an umbrella view of the current state and directions in deep learning for pharma R&D and give a big picture of the business areas within the pharmaceutical companies where deep learning technologies may have transformative effects. Dr. Zhavoronkov will also take part in the panel discussion "Future considerations for blockchain in healthcare and Pharma R&D" that will focus on the latest advances in blockchain for healthcare and drug discovery.

"We are very happy to ?oordinate the AI & Blockchain Applications in Pharma R&D Executive Workshop, which gathers many pharma thought leaders. The topic of AI and Blockchain for healthcare and drug discovery is rapidly gaining popularity and we are happy to be at the leading edge of research and one of the innovation drivers in this area", said Alex Zhavoronkov, PhD, the founder and CEO of Insilico Medicine, Inc.

NextLevel Pharma is a leading, strategic business information provider and opportunity facilitator for the international life sciences industry. The company organizes events that serve as a platform where senior executives, leading experts and key stakeholders meet together to share ideas, achieve critical insights and discover practical solutions to enhance medical innovation for patient benefit.

###

Insilico Medicine is regularly publishing research papers in peer-reviewed journals. It is the first company applied deep generative adversarial networks (GANs) to the generation of new molecular structures with specified parameters and published seminal papers in Oncotarget and Molecular Pharmaceutics. Another paper published in Molecular Pharmaceutics in 2016 and demonstrated the proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. One of the recent papers published in November 2017 described the application of the next-generation AI and blockchain technologies to return the control over personal data back to the individual. One of the latest paper published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The most recent paper published in the Oncotarget journal presented the roadmap to enhancing radioresistance for space exploration and colonization.

For further information, images or interviews, please contact:

Contact: Qingsong Zhu, PhD
zhu@pharma.ai
Website: http://www.Insilico.com

Official Workshop Website: https://www.nextlevells.com/aiblock18-workshop

About Insilico Medicine, Inc

Insilico Medicine, Inc. is an artificial intelligence company headquartered at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D and management resources in Belgium, Russia, UK, Taiwan and Korea sourced through hackathons and competitions.

The company utilizes advances in genomics, big data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI and Aging.AI and operates Chemistry.AI intended to capture the tacit knowledge of medicinal chemists.

Through a partnership with the BitFury Group, the company is working on a range of AI solutions for blockchain to help return the power over life data back to the individual. The company raised venture capital and partnered with Juvenescence Limited, a holding company focused on longevity biotechnology. The company aspires to become the "Bell Labs" for artificial intelligence and associated technologies for healthcare and longevity biotechnology and commercialize its research by forming subsidiaries around the specific technologies and licensing the intellectual property, molecules and data to the biotechnology and pharmaceutical companies. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named the one of the global top 100 AI companies by CB Insights. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.